Literature DB >> 21745171

A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients.

Michele Malagola1, Cristina Skert, Marco Vignetti, Alfonso Piciocchi, Giovanni Martinelli, Giuliana Alimena, Cristina Mecucci, Nicoletta Testoni, Ilaria Iacobucci, Marino Clavio, Marco Gobbi, Anna Candoni, Daniela Damiani, Monica Bocchia, Francesco Lauria, Alfonso Zaccaria, Patrizio Mazza, Giuseppe Visani, Annalisa Peli, Chiara Colombi, Valeria Cancelli, Marco Mancini, Robin Foà, Massimo Martelli, Nicola Cantore, Francesco Di Raimondo, Mario Petrini, Paolo De Fabritiis, Giuseppe Fioritoni, Francesco Nobile, Francesco Fabbiano, Giorgina Specchia, Michele Baccarani, Francesco Lo Coco, Sergio Amadori, Franco Mandelli, Domenico Russo.   

Abstract

We retrospectively analyzed the data of 337 patients with cytogenetically normal (CN) acute myeloid leukemia (AML), aged ≤ 65 years (training set). A prognostic index score (PIS) was calculated by totaling the score derived from the regression coefficients of each clinical variable, significantly associated with prognosis by multivariate analysis. The variables that were independent prognostic factors for event-free survival (EFS) and overall survival (OS) in the training set were: age ≥ 50 years, secondary AML and white blood cell count (WBC) ≥ 20 × 10(9)/L. The patients of the training set were stratified into three groups: low-, intermediate- and high-risk. The median EFS was 25, 12 and 7 months in the low-, intermediate- and high-risk groups (p < 0.0001), respectively. The median OS was not reached in the low-risk group and was 19 and 10 months in the intermediate- and high-risk groups (p < 0.0001). This PIS was validated in a series of 193 patients with CN-AML. The median EFS was 66, 16, and 3 months (p < 0.0001) and the median OS was 66, 16, and 5 months in the three risk groups, respectively (p < 0.0001). This PIS may be useful for clinical decision-making in CN-AML and may be prospectively integrated with the newest biological markers which at present are not routinely assessed and need prognostic validation.

Entities:  

Mesh:

Year:  2011        PMID: 21745171     DOI: 10.3109/10428194.2011.596965

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  2 in total

1.  Comprehensive prognostic scoring systems could improve the prognosis of adult acute myeloid leukemia patients.

Authors:  Fan Zhou; Fen Zhou; Mengyi Du; Lin Liu; Tao Guo; Linghui Xia; Runming Jin; Yu Hu; Heng Mei
Journal:  Int J Hematol       Date:  2019-08-22       Impact factor: 2.490

2.  Easily manageable prognostic factors in 152 Chinese elderly acute myeloid leukemia patients: a single-center retrospective study.

Authors:  Jiadai Xu; Tingmei Chen; Yun Liu; Huayuan Zhu; Wei Wu; WenYi Shen; Bei Xu; Sixuan Qian; Jianyong Li; Peng Liu
Journal:  J Biomed Res       Date:  2014-02-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.